FARN — Faron Pharmaceuticals Oy Share News
0.000.00%
Last trade - 00:00- £193.94m
- £201.65m
Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of New Shares
AnnouncementFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
AnnouncementFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: PDMR Dealing
AnnouncementFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
AnnouncementComposition of Faron Pharmaceutical’s Shareholders’ Nomination Board
AnnouncementFaron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement
AnnouncementREG - AIM - AIM Notice - 05/12/2025
AnnouncementFaron Pharmaceuticals Ltd: Holding(s) in Company
AnnouncementFaron Pharmaceuticals Ltd: Registration of New Shares
AnnouncementFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
AnnouncementFaron Pharmaceuticals Ltd: Grant of Options
AnnouncementFaron Pharmaceuticals Ltd: Appointment of CFO
AnnouncementFaron’s Financial Calendar for 2026
AnnouncementINSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT
AnnouncementREG - AIM - AIM Notice - 29/10/2025
AnnouncementFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
AnnouncementFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
AnnouncementUpdated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients
AnnouncementREG - AIM - AIM Notice - 10/10/2025
Announcement